<HTML xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki  ltr ns-0 ns-subject page-Team_UCL_London_Research_Supercoiliology_ProsAndCons"><DIV id="globalWrapper"><DIV id="top-section"><DIV id="p-logo"><A href="/Main_Page" title="Main Page">&quot;
	    </A></DIV><DIV id="menubar" class="left-menu noprint"><UL><LI class="selected"><A href="/Team:UCL_London/Research/Supercoiliology/ProsAndCons">Page               </A></LI><LI class="new"><A href="/wiki/index.php?title=Talk:Team:UCL_London/Research/Supercoiliology/ProsAndCons&amp;action=edit&amp;redlink=1">Discussion               </A></LI><LI><A href="/wiki/index.php?title=Team:UCL_London/Research/Supercoiliology/ProsAndCons&amp;action=edit">View source               </A></LI><LI><A href="/wiki/index.php?title=Team:UCL_London/Research/Supercoiliology/ProsAndCons&amp;action=history">History               </A></LI><LI style="color:#808080;cursor:default">teams</LI></UL></DIV><DIV class="right-menu noprint" id="menubar"><UL><LI id="pt-login"><A href="/wiki/index.php?title=Special:UserLogin&amp;returnto=Team:UCL_London/Research/Supercoiliology/ProsAndCons" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o">Log in</A></LI></UL></DIV><DIV id="search-controls" class="noprint"><FORM action="/Special:Search" id="searchform"> </FORM></DIV></DIV><DIV id="content"><H1 class="firstHeading">Team:UCL London/Research/Supercoiliology/ProsAndCons</H1><DIV id="bodyContent"><H3 id="siteSub" class="noprint">From 2011.igem.org</H3><DIV id="ecoili"><DIV id="submenu" class="sm-medical-dnavaccines"><UL><LI class="li-150"><A href="/Team:UCL_London/Medicine/DNAVaccines" title="Team:UCL London/Medicine/DNAVaccines">What are they?</A></LI><LI class="li-150"><A href="/Team:UCL_London/Medicine/DNAVaccines/How" title="Team:UCL London/Medicine/DNAVaccines/How">How do they work?</A></LI><LI class="li-150"><A href="/Team:UCL_London/Medicine/DNAVaccines/Delivery" title="Team:UCL London/Medicine/DNAVaccines/Delivery">Delivery</A></LI><LI class="li-150"><A href="/Team:UCL_London/Medicine/DNAVaccines/Toxicology" title="Team:UCL London/Medicine/DNAVaccines/Toxicology">Toxicology</A></LI><LI class="li-150"><A href="/Team:UCL_London/Medicine/DNAVaccines/Methods" title="Team:UCL London/Medicine/DNAVaccines/Methods">Alternatives</A></LI><LI class="li-150"><A href="/Team:UCL_London/Medicine/DNAVaccines/Plasmids" title="Team:UCL London/Medicine/DNAVaccines/Plasmids">Plasmids</A></LI></UL></DIV><DIV id="content"><H1><SPAN class="mw-headline" id="Assessment_of_Advantages_.26_Disadvantages">Assessment of Advantages &amp; Disadvantages</SPAN></H1><P><B>Economies of scale and good biosafety</B></P><P>PICTURE
</P><P>DNA plasmids are facile to manipulate and hence rapid to construct, a critical attribute for making vaccines against an emerging pandemic threat[1]. They are also relatively easy to manufacture, and the process is generic, in contrast to the complicated processes needed for vaccines such as attenuated viruses. One can make the constructs without having to even work with the live pathogen, since the genes encoding the antigens can be constructed chemically rather than by needing to derive them from the live virulent organism. 
</P><P>The plasmids are fairly stable at room temperature, again in contrast to a number of live vaccines whose storage and global delivery are complicated by the need to keep the vaccines cold[2]. Because the DNA vaccines consist simply of a plasmid without other antigens, such as a viral or bacterial vector would have, no issues related to prior-exposure to the pathogen arise. 
</P><P>The constructs can easily be made to code for proteins that have been modified to eliminate regions that have either functions or immunologic properties that are deleterious, thus improving on the proteins and antigens as delivered by the wild type agent in terms of both immunogenicity and safety[3].
</P><P><B>Humoral (antibody) response</B></P><P>A TABLE
</P><P><B>Delivery method</B></P><P>ANOTHER TABLE
</P><P><B>Side effects</B></P><P>Despite ample toxicology evidence indicating that DNA vaccines and their delivery methods are safe in preclinical trials (please refer to toxicology section), we cannot rule out the possibility that side effects may still be felt by the patient during clinical trials, even though theoretically this third generation vaccine has been invented for the sole purpose of facilitating symptomless, holistic, and effective immunity. 
</P><P>There are speculations that extended immunostimulation will lead to acute and/or chronic inflammation and that may lead to destruction of normal tissues[4]. It may also generate autoimmune diseases in the patient such as autoimmune myositis and anti-DNA antibodies[5], which compromise vaccine efficacy and develop tolerance within the host.
</P><P>Last but not least, despite numerous major genetic breakthroughs achieved in recent years, we are still sometimes dealing with the unknown with genetic vaccines. There is the slightest chance that modification to a DNA sequence can cascade into a geneticist’s worst nightmare of insertional mutagenesis, chromosome instability, turning on oncogenes and turning off tumor suppressor genes[6].
</P></DIV><DIV id="footer"><A href="/Team:UCL_London/Team" title="Team:UCL London/Team">Team</A> | <A href="/Team:UCL_London/Data" title="Team:UCL London/Data">Data</A> | <A href="/Team:UCL_London/Safety" title="Team:UCL London/Safety">Safety</A> | <A href="/Team:UCL_London/Attributions" title="Team:UCL London/Attributions">Attributions</A> | <A href="/Team:UCL_London/Partners" title="Team:UCL London/Partners">Partners</A> | <A href="/Team:UCL_London/Bibliography" title="Team:UCL London/Bibliography">Bibliography</A> | <A href="/Team:UCL_London/Protocols" title="Team:UCL London/Protocols">Protocols</A> | <A href="http://partsregistry.org/cgi/partsdb/pgroup.cgi?pgroup=iGEM2011&amp;group=UCL_London" target="_blank">Registry of Parts</A> | <A href="http://www.ucl.ac.uk/biochemeng/index.html" target="_blank">UCL Biochemical Engineering</A></DIV><DIV class="printfooter">
Retrieved from &quot;<A href="http://2011.igem.org/Team:UCL_London/Research/Supercoiliology/ProsAndCons">http://2011.igem.org/Team:UCL_London/Research/Supercoiliology/ProsAndCons</A>&quot;</DIV></DIV></DIV><DIV id="footer-box" class="noprint"><DIV id="footer"><UL id="f-list"><LI id="t-recentchanges"><A href="/Special:RecentChanges" title="Recent changes">Recent changes</A></LI><LI id="t-whatlinkshere"><A href="/Special:WhatLinksHere/Team:UCL_London/Research/Supercoiliology/ProsAndCons" title="List of all wiki pages that link here [j]" accesskey="j">What links here</A></LI><LI id="t-recentchangeslinked"><A href="/Special:RecentChangesLinked/Team:UCL_London/Research/Supercoiliology/ProsAndCons" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</A></LI><LI id="t-specialpages"><A href="/Special:SpecialPages" title="List of all special pages [q]" accesskey="q">Special pages</A></LI><LI><A href="/Special:Preferences">My preferences</A></LI></UL></DIV><DIV id="footer"><UL id="f-list"><LI id="t-print"><A href="/wiki/index.php?title=Team:UCL_London/Research/Supercoiliology/ProsAndCons&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</A></LI><LI id="t-permalink"><A href="/wiki/index.php?title=Team:UCL_London/Research/Supercoiliology/ProsAndCons&amp;oldid=118039" title="Permanent link to this revision of the page">Permanent link</A></LI><LI id="privacy"><A href="/2011.igem.org:Privacy_policy" title="2011.igem.org:Privacy policy">Privacy policy</A></LI><LI id="disclaimer"><A href="/2011.igem.org:General_disclaimer" title="2011.igem.org:General disclaimer">Disclaimers</A></LI></UL></DIV></DIV></DIV></DIV></BODY></HTML>